As Volpe et al. noticed in their Commentary, “the clinical development of this innovative ANP-based, cGMP stimulating therapy, targeting a key mechanism in hypertension may provide a progress in ANP-based therapies and offer a new tool for the treatment of hypertension and its sequelae” (76). This evidence concerns the gene NPPA and hypertensive disorder.